Last updated on September 2018

One-year Persistence to Treatment of Participants Receiving Flixabi: a French Cohort Study


Brief description of study

A study to describe the one-year persistence (participants still treated by Flixabi at 12 Months) in participants treated by Flixabi (infliximab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA), Crohn's Disease (CD) [adults and children] and Ulcerative Colitis (UC) [adults and children].

Clinical Study Identifier: NCT03662919

Contact Investigators or Research Sites near you

Start Over

US Biogen Clinical Trial Center

Research Site
Bobigny, France
3.12miles
  Connect »

US Biogen Clinical Trial Center

Research Site
Creteil, France
5.08miles
  Connect »

US Biogen Clinical Trial Center

Research Site
Clichy, France
7.11miles
  Connect »